Drugs / ICG318
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07715136 | Mar 2025 → Dec 2027 expected | idiopathic inflammatory myopathy | iCell Gene Therapeutics | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07544160 | Apr 2026 → Apr 2028 expected | inflammatory bowel disease | iCell Gene Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07328581 | Jan 2026 → Dec 2028 expected | lupus nephritis, systemic lupus erythematosus | iCell Gene Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICG318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07715136 ↗ |
| Known as | ICG318 CAR-T | “ICG318 CAR-T, the investigational agent in this clinical trial, is an armored, compound chimeric antigen receptor (cCAR) composed of two independently functioning CARs that...” NCT07544160 ↗ |
| Modality | Cell therapy | “Anti-BCMA, Anti-CD19 Compound CAR-T cells” NCT07715136 ↗ |